Items where authors include "Waddell, T."

Article

Culliford, R. orcid.org/0000-0003-4534-9241, Lawrence, S.E.D., Mills, C. orcid.org/0000-0002-4755-7549 et al. (40 more authors) (2024) Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma. Nature Communications, 15. 5935. ISSN 2041-1723

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G., Brown, S. et al. (24 more authors) (2023) Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology. ISSN 0732-183X

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G. orcid.org/0000-0002-9952-8440, Brown, S. orcid.org/0000-0002-7975-7537 et al. (24 more authors) (2023) Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized phase II trial (PRISM). Journal of Clinical Oncology. JCO2300236. ISSN 0732-183X

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Smyth, E.C., Cafferkey, C., Loehr, A. et al. (17 more authors) (2018) Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget, 9 (94). pp. 36654-36665. ISSN 1949-2553